Vildagliptin: An anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 12, 2013, Pages 1773-1784

  Kosaraju, Jayasankar ^a   Murthy, Vishakantha ^b   Khatwal, Rizwan Basha ^a   Dubala, Anil ^a   Chinni, Santhivardhan ^a   Muthureddy Nataraj, Satish Kumar ^a   Basavan, Duraiswamy ^a  

^a JSS COLLEGE OF PHARMACY   (India)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

amyloid beta; dipeptidyl peptidase 4; glucagon like peptide 1; tau; type 2 diabetes

Indexed keywords

AMYLOID BETA PROTEIN; GLUCAGON LIKE PEPTIDE 1; TAU PROTEIN; VILDAGLIPTIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; HIPPOCAMPUS; HISTOPATHOLOGY; INFLAMMATION; MALE; MEMORY CONSOLIDATION; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT;

AMYLOID BETA; DIPEPTIDYL PEPTIDASE-4; GLUCAGON-LIKE PEPTIDE-1; TAU; TYPE 2 DIABETES;

ADAMANTANE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; COGNITION DISORDERS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HIPPOCAMPUS; HYPOGLYCEMIC AGENTS; INTERLEUKIN-1BETA; MALE; MAZE LEARNING; NITRILES; PYRROLIDINES; RATS; RATS, WISTAR; STREPTOZOCIN; TAU PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84888008405     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12148     Document Type: Article

References (51)

1. Glenner GG, Wong CW,. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120: 885-890.
2. Masters CL, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985; 82: 4245-4249.
3. Goedert M, et al. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 1992; 8: 159-168.
4. Li L, Holscher C,. Common pathological processes in Alzheimer's disease and type 2 diabetes: a review. Brain Res Rev 2007; 56: 384-402.
5. Perry T, Greig NH,. The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. J Alzheimers Dis 2002; 4: 487-496.
6. Green BD, et al. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 2006; 3: 159-165.
7. Kastin AJ, et al. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002; 18: 7-14.
8. Hamilton A, Holscher C,. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 2009; 20: 1161-1166.
9. Holscher C,. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat CNS Drug Discov 2010; 5: 109-117.
10. Gengler S, et al. Val(8) GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging 2010; 33: 265-276.
11. D'Amico M, et al. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp Gerontol 2010; 45: 202-207.
12. Mathieu C, Degrande E,. Vildagliptin: a new oral treatment for type 2 diabetes mellitus. Vasc Health Risk Manag 2008; 4: 1349-1360.
13. Sharma M, Gupta YK,. Intrecerbroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. Life Sci 2001; 68: 1021-1029.
14. Sehgal N, et al. Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci U S A 2012; 109: 3510-3515.
15. Froelich L, et al. Holeboard maze-learning deficits and brain monoaminergic neurotransmitter concentrations in rats after intracerebroventricular injection of 3-Bromopyruvate. Pharmacol Biochem Behav 1995; 51: 917-922.
16. Grunblatt E, et al. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 2007; 101: 757-770.
17. Park OK, et al. Comparison of neuroprotective effects of five major lipophilic diterpenoids from Danshen extract against experimentally induced transient cerebral ischemic damage. Fitoterapia 2012; 83: 1666-1674.
18. Hardy J, Selkoe DJ,. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
19. Tariot PN, Federoff HJ,. Current treatment for Alzheimer disease and future prospects. Alzheimer Dis Assoc Disord 2003; 17: S105-S113.
20. Tariot PN, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. J Am Med Assoc 2004; 291: 317-324.
21. Reisberg B, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-1341.
22. Grutzendler J, Morris JC,. Cholinesterase inhibitors for Alzheimer's disease. Drugs 2001; 61: 41-52.
23. Kavirajan H, Schneider LS,. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007; 6: 782-792.
24. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement 2012; 8: 131-168.
25. Hamaguchi T, et al. Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. Cell Mol Life Sci 2006; 63: 1538-1552.
26. Findeis MA,. The role of amyloid β peptide 42 in Alzheimer's disease. Pharmacol Ther 2007; 116: 266-286.
27. Fodero-Tavoletti MT, et al. Amyloid-β: the seeds of darkness. Int J Biochem Cell Biol 2011; 43: 1247-1251.
28. Lester-Coll N, et al. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 2006; 9: 13-33.
29. de la Monte SM, Wands JR,. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis 2005; 7: 45-61.
30. Adeghate E, et al. Alzheimer disease and diabetes mellitus: do they have anything in Common? Curr Alzheimer Res 2013; 10: 609-617.
31. Salkovic-Petrisic M, et al. Modeling sporadic Alzheimer's disease: the insulin resistant brain state generates multiple long-term morphobiological abnormalities including hyperphosphorylated tau protein and amyloid-beta. J Alzheimers Dis 2009; 18: 729-750.
32. Jarrett JT, et al. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993; 32: 4693-4697.
33. El-Agnaf OM, et al. Oligomerization and toxicity of beta-amyloid-42 implicated in Alzheimer's disease. Biochem Biophys Res Commun 2000; 273: 1003-1007.
34. Yamazaki K, et al. 7-but-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1- yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity. J Pharmacol Exp Ther 2006; 319: 1253-1257.
35. During MJ, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9: 1173-1179.
36. Kosik KS, et al. Developmentally regulated ex-pression of specific tau sequences. Neuron 1989; 4: 1389-1397.
37. Alonso A, et al. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight fila-ments. Proc Natl Acad Sci U S A 2001; 98: 6923-6928.
38. Mandelkow E, et al. On the struc-ture of microtubules, tau, and paired helicalfilaments. Neurobiol Aging 1995; 16: 347-354.
39. Li L, et al. Val8) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. Eur J Pharmacol 2012; 674: 280-286.
40. Chen S, et al. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4. Age (Dordr) 2012; 34: 1211-1224.
41. Sharma B, et al. Modulation of celecoxib- and streptozotocin-induced experimental dementia of Alzheimer's disease by Pitavastatin and Donepezil. J Psychopharmacol 2008; 22: 162-171.
42. Tiwari V, et al. Chronic treatment with Tocotrienol, an isoform of vitamin E, prevents intracerebroventricular streptozotocin-induced cognitive impairment and oxidative-nitrosative stress in rats. Pharmacol Biochem Behav 2009; 93: 183-189.
43. Tota S, et al. Improvement of brain energy metabolism and cholinergic functions contributes to the beneficial effects of silibinin against streptozotocin induced memory impairment. Behav Brain Res 2011; 221: 207-215.
44. Wang YJ, et al. Consumption of grape seed extract prevents amyloid-β deposition and attenuates inflammation in brain of an Alzheimer's disease mouse. Neurotox Res 2009; 15: 3-14.
45. Prakash AK, Kumar A,. Effect of chronic treatment of Carvedilol on oxidative stress in an intracerebroventricular streptozotocin induced model of dementia in rats. J Pharm Pharmacol 2009; 61: 1665-1672.
46. Dickson DW,. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997; 56: 321-339.
47. Apelt J, Schliebs R,. Beta-amyloid-induced glial expression of both pro- and anti- inflammatory cytokines in cerebral cortex of aged and transgenic transgenicTg2576 mice with Alzheimer plaque pathology. Brain Res 2001; 894: 21-30.
48. Wyss-Coray T,. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006; 12: 1005-1015.
49. Shiraki A, et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 2012; 221: 375-382.
50. McClean PL, et al. The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011; 31: 6587-6594.
51. Perry T, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003; 72: 603-612.